Literature DB >> 11875670

Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura.

Deborah Kees-Folts1, Arthur B Abt, Ronald E Domen, Andrew S Freiberg.   

Abstract

Idiopathic thrombocytopenic purpura (ITP) is a disorder of rapid destruction of antibody-coated platelets. Anti-D immune globulin has been used for treatment of ITP in the United States since 1995. Initial studies identified no significant side effects of treatment. However, a recent report highlighted occasional episodes of intravascular hemolysis after anti-D immune globulin. We describe two children with ITP who developed acute renal failure (ARF) after treatment with anti-D immune globulin and also analyze ten additional cases of ARF reported to the manufacturer, Cangene Corporation, through postmarketing surveillance. All episodes of ARF were associated with intravascular hemolysis. Four patients required dialysis. Patient age ranged from 1 to 82 years, but those requiring dialysis were all under age 15 years. Several patients with ARF had preexisting creatinine elevation. Three of the patients with ARF had serologic evidence of acute Epstein-Barr virus (EBV) infection. Renal biopsy in one patient showed acute tubular necrosis, with findings consistent with pigment nephropathy. Anti-D immune globulin, used to treat ITP, may be associated with intravascular hemolysis and resultant ARF. Renal function should be monitored in patients with evidence of intravascular hemolysis. Children and adolescents may have increased risk of ARF requiring dialysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875670     DOI: 10.1007/s00467-001-0763-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  4 in total

Review 1.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

Review 2.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

3.  Trends in anti-D immune globulin for childhood immune thrombocytopenia: usage, response rates, and adverse effects.

Authors:  Michelle Long; Leslie A Kalish; Ellis J Neufeld; Rachael F Grace
Journal:  Am J Hematol       Date:  2011-12-21       Impact factor: 10.047

4.  Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model.

Authors:  Ann Reed Gaines; Hallie Lee-Stroka; Karen Byrne; Dorothy E Scott; Lynne Uhl; Ellen Lazarus; David F Stroncek
Journal:  Transfusion       Date:  2009-02-09       Impact factor: 3.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.